Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Diazepam Rectal Gel Articles

GSK to promote Valeant drugs

3 November 2008

Amarin licenses nasal lorazepam from Elan

12 March 2007

Valeant sales rise 22%

16 May 2005

Elan Corp gains approval of Zonegran in USA for epilepsy

29 March 2000

Draxis launches Diastat in Canada

24 February 2000

Revenues Rise 63% At Ireland's Elan Corp In Third Quarter

27 October 1998

Elan's Zonisamide Nears US Approval

25 March 1998

Strong Growth At Elan Corp, Net Income Up 51%

9 February 1998

Net Income And EPS Soar At Ireland's Elan Corp

22 October 1997

Elan's Diastat Approved In USA

31 July 1997

Epilepsy Market Sees Strong Growth

29 July 1997

FDA Approves Elan's Zanaflex For Spasticity

9 December 1996

Athena's Diastat Backed In USA

25 November 1996

Athena Files For Diastat In USA

12 February 1996

Showing 1-14 of 14 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS